Table 2.
Baseline characteristics of patients who developed and did no develop hypocalcemia within 12 months after cinacalcet initiation
| Characteristic | No hypocalcemia N = 295 | Hypocalcemia N = 610 | Patients who develop hypocalcemia within 12 months (N = 610) | ||
|---|---|---|---|---|---|
| Mild Ca 2.0– < 2.1 mmol/L N = 415 | Moderate Ca 1.87– < 2.0 mmol/L N = 141 | Severe Ca < 1.87 mmol/L N = 54 | |||
| Patient age at index date [years]a | 66 (54, 75) | 67 (54, 76) | 67 (54, 77) | 66 (55, 75) | 69 (60, 77) |
| Male, no. (%) | 173 (59) | 352 (58) | 240 (58) | 82 (58) | 30 (56) |
| Geographical area, no. (%) | |||||
| Eastern Europeb | 25 (9) | 56 (9) | 38 (9) | 15 (11) | 3 (6) |
| Western Europec | 33 (11) | 41 (7) | 28 (7) | 8 (6) | 5 (9) |
| Iberian Peninsulad | 237 (80) | 513 (84) | 349 (84) | 118 (84) | 46 (85) |
| BMI [kg/m2]a | 26.9 (24.0, 31.0) | 27.0 (24.3, 30.2) | 26.9 (24.2, 30.2) | 27.2 (24.3, 30.3) | 27.5 (25.5, 30.0) |
| BMI [kg/m2]—category, No. (%) | |||||
| < 18.5 | 4 (1) | 7 (1) | 6 (1) | 1 (1) | 0 (0) |
| ≥ 18.5–< 25 | 79 (27) | 162 (27) | 115 (28) | 37 (26) | 10 (19) |
| ≥ 25–< 30 | 101 (34) | 232 (38) | 154 (37) | 54 (38) | 24 (44) |
| ≥ 30 | 75 (25) | 148 (24) | 102 (25) | 35 (25) | 11 (20) |
| Missing | 36 (12) | 61 (10) | 38 (9) | 14 (10) | 9 (17) |
| Clinical history, no. (%) | |||||
| Hospitalisation | 137 (46) | 310 (51) | 207 (50) | 71 (50) | 32 (59) |
| Diabetes | 89 (30) | 194 (32) | 128 (31) | 46 (33) | 20 (37) |
| Cancer | 26 (9) | 59 (10) | 42 (10) | 11 (8) | 6 (11) |
| Cardiovascular disease | 131 (44) | 304 (50) | 199 (48) | 77 (55) | 28 (52) |
| Fracture | 14 (5) | 29 (5) | 21 (5) | 6 (4) | 2 (4) |
| Dialysis duration per week [hours]a | 12.0 (12.0, 12.4) | 12.0 (12.0, 12.3) | 12.0 (12.0, 12.3) | 12.0 (12.0, 12.4) | 12.0 (12.0, 12.0) |
| Dialysis adequacy [Kt/V]–category, no. (%) | 39 (13) | 88 (14) | 53 (13) | 23 (16) | 12 (22) |
| < 1.2 | 229 (78) | 474 (78) | 320 (77) | 112 (79) | 42 (78) |
| ≥ 1.2 | 27 (9) | 48 (8) | 42 (10) | 6 (4) | 0 (0) |
| Dialysis vintage [years]a | 2.0 (1.0, 3.5) | 1.8 (1.0, 3.0) | 1.8 (1.0, 3.1) | 1.8 (0.9, 3.0) | 1.7 (0.9, 2.3) |
| Dialysate calcium [mmol/L]a | 1.3 (1.3, 1.5) | 1.3 (1.3, 1.5) | 1.3 (1.3, 1.5) | 1.3 (1.3, 1.5) | 1.5 (1.3, 1.5) |
| Catheter vascular access, no. (%) | |||||
| Yes | 37 (13) | 158 (26) | 99 (24) | 34 (24) | 25 (46) |
| No | 246 (83) | 434 (71) | 306 (74) | 101 (72) | 27 (50) |
| Missing | 12 (4) | 18 (3) | 10 (2) | 6 (4) | 2 (4) |
| Net ultrafiltration [L]a | 2.0 (1.4, 2.7) | 2.1 (1.4, 2.7) | 2.0 (1.4, 2.7) | 2.1 (1.5, 2.6) | 2.3 (1.7, 3.0) |
| Blood haemoglobin [g/L]a | 118 (110, 126) | 120 (112, 127) | 119 (111, 127) | 121 (112, 127) | 119 (113, 127) |
| Serum albumin [g/L]a | 41.0 (38.4, 43.0) | 40.0 (37.0, 42.2) | 40.0 (37.9, 42.1) | 39.2 (37.0, 43.0) | 38.4 (36.0, 42.0) |
| Serum ferritin [µg/L]a | 430 (244, 639) | 398 (260, 599) | 410 (267, 620) | 382 (242, 544) | 376 (236, 572) |
| Serum CRP [mg/L]a | 4.1 (1.7, 9.2) | 4.9 (2.0, 11.0) | 4.7 (1.8, 10.0) | 5.0 (2.0, 12.3) | 7.4 (2.8, 17.7) |
| Serum calcium [mmol/L]a | 2.4 (2.3, 2.5) | 2.3 (2.2, 2.4) | 2.3 (2.2, 2.4) | 2.3 (2.2, 2.4) | 2.3 (2.2, 2.3) |
| Serum calcium [mmol/L]—category, no. (%) | |||||
| ≥ 2.10–< 2.50 | 216 (73) | 546 (90) | 367 (88) | 131 (93) | 48 (89) |
| ≥ 2.50–< 2.75 | 67 (23) | 60 (10) | 44 (11) | 10 (7) | 6 (11) |
| ≥ 2.75 | 12 (4) | 4 (1) | 4 (1) | 0 (0) | 0 (0) |
| Serum phosphate [mmol/L]a | 1.7 (1.4, 2.0) | 1.7 (1.4, 2.0) | 1.7 (1.4, 2.0) | 1.7 (1.5, 2.0) | 1.7 (1.3, 1.9) |
| Serum PTH [ng/L]a | 545 (415, 761) | 606 (442, 837) | 580 (434, 833) | 624 (446, 864) | 677 (463, 824) |
| Corrected Ca [mmol/L]a | 2.4 (2.3, 2.5) | 2.3 (2.2, 2.4) | 2.3 (2.3, 2.4) | 2.3 (2.2, 2.4) | 2.3 (2.2, 2.4) |
| Corrected Ca [mmol/L], no. (%) | |||||
| ≥ 2.10–< 2.50 | 190 (64) | 504 (83) | 342 (82) | 119 (84) | 43 (80) |
| ≥ 2.50–< 2.75 | 73 (25) | 68 (11) | 47 (11) | 14 (10) | 7 (13) |
| ≥ 2.75 | 14 (5) | 4 (1) | 4 (1) | 0 (0) | 0 (0) |
| Missing | 18 (6) | 34 (6) | 22 (5) | 8 (6) | 4 (7) |
| Drug use, no. (%) | |||||
| Calcitriol/alfacalcidol | 75 (25) | 149 (24) | 98 (24) | 41 (29) | 10 (19) |
| Paricalcitol | 127 (43) | 265 (43) | 186 (45) | 60 (43) | 19 (35) |
| Phosphate binder use, no. (%) | |||||
| Non-calcium based only | 136 (46) | 257 (42) | 187 (45) | 50 (36) | 20 (37) |
| Calcium based only | 26 (9) | 66 (11) | 41 (10) | 19 (14) | 6 (11) |
| Both calcium based and non-calcium based | 71 (24) | 137 (23) | 96 (23) | 31 (22) | 10 (19) |
| None | 62 (21) | 150 (25) | 91 (22) | 41 (29) | 18 (33) |
aMedian (Q1, Q3)
bEastern Europe: Czech Republic, Hungary, Poland, Romania, Russia, Serbia, Slovak Republic, Slovenia and Turkey
cWestern Europe: France, Ireland, Italy, and the United Kingdom
dIberian Peninsula: Portugal and Spain